Safety study of IMSB301 for type 1 interferon disorders
Part of Immune system & allergy clinical trials.
This study tests an experimental drug (IMSB301) for people with rare genetic conditions that cause too much type 1 interferon activity (a part of the immune system). The goal is to see if the drug is safe and can help reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old and weigh at least 40 kg (about 88 lbs).
- You must have a specific genetic diagnosis, like Aicardi-Goutieres Syndrome, familial chilblain lupus, or certain lupus types confirmed by a gene test.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have had a serious infection, active infection, or certain infections like HIV, hepatitis, or TB.
- You must not have taken certain medications like JAK inhibitors or interferon blockers within the past few weeks or months.
- You cannot have a history of most cancers, a BMI over 33, or certain heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a protein called type I interferon, which is often too high in people with autoimmune diseases. The goal is to better understand how it relates to these conditions, which may help improve future treatments.
This study looks at people with a confirmed type 1 interferonopathy, a rare immune condition caused by a gene change. It aims to learn more about how the condition progresses over time.
This study is for adults whose immune system has trouble fighting viruses due to specific antibodies or a genetic condition. Researchers want to follow these people over time to better understand the condition and improve care.
This study tests a new treatment that blocks a protein called type 1 interferon, which may reduce inflammation and pain in severe hidradenitis suppurativa. It is for people who have not improved with standard treatments like antibiotics or biologic drugs.
This study tests a new drug called RXIM002 for people with severe autoimmune diseases that haven't improved with standard treatments. It aims to see if targeting immune cells with the CD19 marker can help control the disease.
This trial tests an investigational drug called IB-001 to see how well it works and how safe it is. It is for healthy volunteers and people with chronic hepatitis B. The goal is to find the best dose and understand side effects.
Hear when a new Type 1 Interferonopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.